E. Bouffet, R. Jakacki, S. Goldman, D. Hargrave, C. Hawkins, M. Shroff, et al., “Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma,” Journal of Clinical Oncology, Vol. 30, No. 12, 2012, pp. 1358-1363.

has been cited by the following article:

• TITLE: Long Lasting Efficiency of Monthly Vinblastine in a Case of Relapsed Anaplastic Large Cell Lymphoma

  AUTHORS: Ratha Mlis, Matthias Schell, Perrine Marec Bérard, Nathalie Bleyzac, Didier Frappaz

  KEYWORDS: Anaplastic Large Cell Lymphoma; Vinblastine

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.3 No.2, June 25, 2013

  ABSTRACT: Nearly 40% of children with Anaplastic Large cell lymphomas will relapse after a first-line strategy with short-pulse chemotherapy and reach a second remission in 30% to 60% with second line therapies including maintenance treatment with vinblastine or allogeneic hematopoietic stem-cell transplantation. The authors report a heavily pretreated case in second relapse who was maintained in third remission for 8 years with monthly vinblastine. He relapsed 16 weeks after discontinuation. This case demonstrates that monthly treatment with vinblastine may be sufficient to maintain a minimal disease. Oral compounds are now available and should be discussed in such situations.